Savara Inc (SVRA)

May 28, 2025, 6:00 AM EDT - 3 days ago

Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

May 27, 2025, 3:40 PM EDT - 4 days ago

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

May 27, 2025, 11:42 AM EDT - 4 days ago

BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

May 27, 2025, 8:05 AM EDT - 4 days ago

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

May 23, 2025, 4:05 PM EDT - 8 days ago

Savara Announces New Employment Inducement Grant

May 22, 2025, 9:05 AM EDT - 9 days ago

Savara Announces Participation in Jefferies Global Healthcare Conference

May 18, 2025, 2:30 PM EDT - 13 days ago

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

May 13, 2025, 4:05 PM EDT - 18 days ago

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

May 12, 2025, 4:05 PM EDT - 19 days ago

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

May 1, 2025, 4:05 PM EDT - 4 weeks ago

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

Apr 21, 2025, 11:16 AM EDT - 5 weeks ago

Savara: Make-It-Or-Break-It Molbreevi BLA Filing

Apr 7, 2025, 4:05 PM EDT - 7 weeks ago

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Mar 27, 2025, 7:05 AM EDT - 2 months ago

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 26, 2025, 4:45 PM EDT - 2 months ago

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

HTGC

Mar 26, 2025, 4:05 PM EDT - 2 months ago

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Mar 17, 2025, 8:05 AM EDT - 2 months ago

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Mar 6, 2025, 8:05 AM EST - 3 months ago

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Mar 3, 2025, 4:15 PM EST - 3 months ago

Savara Announces Participation in the Leerink Global Healthcare Conference

Jan 30, 2025, 8:39 AM EST - 4 months ago

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Jan 29, 2025, 4:05 PM EST - 4 months ago

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Dec 18, 2024, 4:05 PM EST - 5 months ago

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Dec 17, 2024, 4:05 PM EST - 5 months ago

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 22, 2024, 8:05 AM EST - 6 months ago

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Nov 13, 2024, 8:05 AM EST - 7 months ago

Savara Announces Participation in Upcoming Healthcare Conferences

Nov 12, 2024, 8:05 AM EST - 7 months ago

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:05 PM EST - 7 months ago

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 22, 2024, 8:05 AM EDT - 7 months ago

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

Oct 1, 2024, 8:05 AM EDT - 8 months ago

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

Sep 27, 2024, 8:05 AM EDT - 8 months ago

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Sep 24, 2024, 8:05 AM EDT - 8 months ago

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

Sep 23, 2024, 8:05 AM EDT - 8 months ago

Savara to Host Analyst and Investor Webinar on September 30, 2024

Sep 8, 2024, 6:45 AM EDT - 9 months ago

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

Sep 3, 2024, 4:05 PM EDT - 9 months ago

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 8:05 AM EDT - 10 months ago

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

Aug 12, 2024, 4:05 PM EDT - 10 months ago

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 28, 2024, 8:50 AM EDT - 1 year ago

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

Jun 26, 2024, 9:36 AM EDT - 1 year ago

Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?

Jun 26, 2024, 6:41 AM EDT - 1 year ago

Savara's rare lung disease drug meets main goal in late-stage study

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Jun 25, 2024, 8:05 PM EDT - 1 year ago

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Jun 7, 2024, 5:56 AM EDT - 1 year ago

Savara: The Binary Bet On Phase 3 Data

May 29, 2024, 8:05 AM EDT - 1 year ago

Savara to Present at the Jefferies Global Healthcare Conference

May 19, 2024, 12:15 PM EDT - 1 year ago

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

May 9, 2024, 4:05 PM EDT - 1 year ago

Savara Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:05 PM EDT - 1 year ago

Savara to Present at the Citizens JMP Life Sciences Conference